Reported numbers of CML patients developing VAEs and peripheral occlusive VAEs (PAOD) during treatment with nilotinib or ponatinib
| No. of patients (n) . | TKI . | VAE % . | PAOD % . | Observation time, mo . | Reference . |
|---|---|---|---|---|---|
| 24 | NI | 25.0 | 16.5 | 24 | 29 |
| 179 | NI | nr | 6.2 | nr | 30 |
| 233 | NI | 2.0 | 1.3 | nr | 47 |
| 556 | NI | 4.9 | 1.3 | 36 | 52 |
| 54 | NI | nr | 13.0 | 26.4 | 55 |
| 66 | NI | nr | 6.0 | nr | 31 |
| 75 | NI | 9.8 | 8.0 | 24 | 54 |
| 19.3 | nr | 36 | |||
| 27.7 | nr | 48 | |||
| 34 | NI | 29.4 | 20.6 | 24 | 53 |
| 38.9 | 33.3 | 36 | |||
| 563 | NI | 7.0 | 1.2 | 48 | 56 |
| 556 | NI | nr | 1.3 | 36 | 44 |
| 27 | NI | nr | 14.8 | 24 | 45 |
| 31 | NI | nr | 9.7 | 31 | 57 |
| 55 | NI | 11.0 | 1.8 | 28 | 58 |
| 98 | NI | nr | 3.1 | 31 | 59 |
| 449 | PO | 8.9 | 4.9 | 11 | 32 |
| 17.1 | 11.8 | 24 |
| No. of patients (n) . | TKI . | VAE % . | PAOD % . | Observation time, mo . | Reference . |
|---|---|---|---|---|---|
| 24 | NI | 25.0 | 16.5 | 24 | 29 |
| 179 | NI | nr | 6.2 | nr | 30 |
| 233 | NI | 2.0 | 1.3 | nr | 47 |
| 556 | NI | 4.9 | 1.3 | 36 | 52 |
| 54 | NI | nr | 13.0 | 26.4 | 55 |
| 66 | NI | nr | 6.0 | nr | 31 |
| 75 | NI | 9.8 | 8.0 | 24 | 54 |
| 19.3 | nr | 36 | |||
| 27.7 | nr | 48 | |||
| 34 | NI | 29.4 | 20.6 | 24 | 53 |
| 38.9 | 33.3 | 36 | |||
| 563 | NI | 7.0 | 1.2 | 48 | 56 |
| 556 | NI | nr | 1.3 | 36 | 44 |
| 27 | NI | nr | 14.8 | 24 | 45 |
| 31 | NI | nr | 9.7 | 31 | 57 |
| 55 | NI | 11.0 | 1.8 | 28 | 58 |
| 98 | NI | nr | 3.1 | 31 | 59 |
| 449 | PO | 8.9 | 4.9 | 11 | 32 |
| 17.1 | 11.8 | 24 |
The patients described in the above-listed investigations were in part from identical cohorts: patients reported in Aichberger et al29 were also included in the report by Le Coutre et al30 and data reported by Giles et al,44 Larsen et al,52 and Saglio et al56 were mostly from patients included in the ENESTnd trial.
NI, nilotinib; nr, not reported; PO, ponatinib.